Results 111 to 120 of about 1,385,819 (261)

MARK4 enhances stress granule formation under oxidative stress and increases tau accumulation

FEBS Open Bio, EarlyView.
MARK4 (red dots) localizes to stress granules (orange dots) and promotes their formation under oxidative stress by modulating TIA1 (blue dots). MARK4 and TIA1 synergistically increase tau (purple) accumulation, and the reduction of the TIA1 ortholog suppresses neurodegeneration in a fly model.
Sho Nakajima, Kotone Watanabe, Grigorii Sultanakhmetov, Aoi Fukuchi, Keiya Ito, Sawako Shimizu, Taro Saito, Akiko Asada, Kanae Ando   +8 more
wiley   +1 more source

Cell-surface markers and monoclonal antibody cocktails.

, 2018
Cell-surface markers and monoclonal antibody cocktails.
Tyson H. Holmes (95098), Kailash C. Aggarwal (728006), Harish K. Chellani (728007), Deepak K. Rathore (728000), Kari C. Nadeau (114674), Satyajit Rath (162592), Uma Chandra Mouli Natchu (250133), Morvarid Tavassoli (5983088), Nitya Wadhwa (728013), Vineeta Bal (162603), Yael Rosenberg-Hasson (5983085), Shailaja Sopory (728012), Holden T. Maecker (286420), Shinjini Bhatnagar (266342), Pratima Mittal (3462962), Rohit Gupta (2642632), Achla Batra (5983082), Deirdre J. Lyell (3920228)   +17 more
core   +1 more source

Dactolisib outperforms Rapamycin in potentiating apoptosis induced by XPO1, Bcl‐2 and Mcl‐1 blockade in preclinical glioblastoma models

FEBS Open Bio, EarlyView.
The PAM pathway and its impact on cellular metabolism. Color‐coded key symbols represent Rapamycin (R, orange, targeting mTOR) and Dactolisib (D, green, targeting PI3K/mTOR), indicating their sites of action. Created with BioRenders.com. Glioblastoma resists therapy through interconnected survival programs.
Kai Zhao, Leonie Meyer, Madita Braun, Katharina Otte, Celine Bitter, Maite Pawlik, Hartmann Raifer, Frederik Helmprobst, Axel Pagenstecher, Hans Urban, Michael C. Burger, Michael W. Ronellenfitsch, Joachim P. Steinbach, Jarmila Jedelská, Shamim Bagheri, Behrooz H. Yousefi, Pietro Di Fazio, Markus Luster, Andreas H. Mahnken, Andreas Neubauer, Andreas Burchert, Christopher Nimsky, Jörg W. Bartsch, Tillmann Rusch   +23 more
wiley   +1 more source

Chronobiology of Cancer: How Aging Fuels Oncogenesis at the Molecular Level

Aging and Cancer, EarlyView.
This graphical abstract illustrates the key biological pathways linking aging with cancer development and progression. In the upper left, cumulative exposure to ultraviolet radiation, toxins, and reactive oxygen species (ROS) causes DNA damage and genomic instability, whereas age‐related decline in repair mechanisms, such as ATM/ATR, BER, and NER ...
Anu Singh, Aroonima Misra, Sufian Zaheer
wiley   +1 more source

Monoclonal antibody therapy of solid tumors: clinical limitations and novel strategies to enhance treatment efficacy

, 2019
Esteban Cruz, Veysel KayserSchool of Pharmacy, The University of Sydney, Sydney, NSW, AustraliaAbstract: Monoclonal antibodies (mAbs) have become a cornerstone in the therapeutic guidelines of a wide range of solid tumors.
Kayser V, Cruz E
core  

Murine Monoclonal Antibodies: 49 Years of Experience—Is it a Spent Technique?

Department of Chemistry and Biochemistry California State UniversityDepartment of Clinical Analysis Monoclonal Antibody Laboratory School of Pharmaceutical Sciences São Paulo State University (UNESP)Department of Clinical Analysis Monoclonal Antibody ...
Brooks, Cory L., Moroz, Andrei [UNESP]
core   +1 more source

Tentacle morphogenesis in hydra [PDF]

, 1990
Differentiation of sensory nerve cells in tentacles of Hydra magnipapillata was investigated using the monoclonal antibody NV1. NV1+ sensory nerve cells form specific complexes with battery cells in tentacles.
Hobmayer, Engelbert, Holstein, Thomas W., David, Charles N.   +2 more
core  

Ofatumumab in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease: A Comparison With Rituximab

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan, Lei Zhou, Jingzi ZhangBao, Hongmei Tan, Zhouzhou Wang, Chao Quan   +5 more
wiley   +1 more source

Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing–Remitting MS

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) levels are believed to reflect mainly acute and chronic disease processes in multiple sclerosis (MS), respectively. In this study, we investigated whether dimethyl fumarate (DMF) and rituximab (RTX) differentially affect these biomarkers.
F. Shawket, J. Lycke, J. Salzer, F. Piehl, K. Fink, N. Lange, J. Mellergård, C. Malmeström, P. Sundström, I. Erngren, A. al‐Grety, E. Freyhult, K. Kultima, J. Burman, A. Svenningsson   +14 more
wiley   +1 more source

Antibody Conjugates via Disulfide Bridging: Towards therapeutic and diagnostic applications [PDF]

, 2015
Antibodies play a prominent role in chemical and biological research and the largest application of chemical bioconjugation reagents is in the production of antibody conjugates.
Hull, EA
core